SQ-LIP-000010 · v1.0 (current) · machine-readable JSON →
Does a lipedema-like (peripheral/gynoid) fat distribution protect against cancer or metabolic disease?
Cross-sectional NHANES analyses found that a higher leg-to-trunk fat ratio was associated with lower cancer prevalence and a more favorable immunometabolic profile. Because these are prevalence (not incidence) data, reverse causation (illness reducing peripheral fat) cannot be excluded; the protective association is suggestive, not established.
Knowledge freshness = share of the 3 indexed evidence sources from the last 5 years (newest 2025, oldest 2025) . Low freshness flags an ageing evidence base — not that the answer is wrong.
Evidence over time
supporting contradicting refining / context Each dot is a study, placed by year and coloured by whether the linked claim supports or contradicts the answer. As the surveillance loop runs, claim revisions and new evidence will extend this timeline.
Choose a format (Vancouver default). Citing a version captures the evidence state on that date; this page shows the current version — see version history.
What changed in this version
Initial version (v1.0): 3 founding claims indexed from the lipedema pilot. The automated surveillance loop (new-article ingestion → supports / contradicts / refines) has not yet run.
Supporting claims
- SCR-LIP-000028 supporting
In NHANES women aged 20-59, a lipedema-like peripheral fat distribution was inversely associated with cancer prevalence: each 1-SD increase in leg-to-trunk fat ratio was associated with 20% lower adjusted odds of cancer (OR 0.795; 95%CI 0.666-0.948; p=0.011).
DOI:10.64898/2025.12.02.25341445 - SCR-LIP-000029 supporting
The inverse association between lipedema-like peripheral fat distribution and cancer prevalence was most robust in women without obesity (OR 0.67 per 1-SD LTR; 95%CI 0.53-0.85; p=0.0007).
DOI:10.64898/2025.12.02.25341445 - SCR-LIP-000027 supporting
In NHANES women, a DXA-defined lipedema-like phenotype (leg-to-trunk fat ratio >90th percentile) was associated with a favorable immunometabolic profile, including 44.2% lower HOMA-IR (p<0.001) and 7.6% lower neutrophil-to-lymphocyte ratio (p=0.012).
DOI:10.64898/2025.12.01.25341350
Contradictory claims
- None indexed yet.
Major uncertainty
Cross-sectional prevalence, self-reported outcomes, reverse causation and survival bias possible.
Version history
- SQ-LIP-000010 · v1.0 — 2026-05-30 — founding index (3 claims) · view this version
Key references
DOI:10.64898/2025.12.02.25341445 · DOI:10.64898/2025.12.01.25341350